From moderate-risk TAVR to PCSK9 inhibitors to exercise in HCM, the American College of Cardiology’s annual Scientific Session brought advancements across many areas of cardiology.
A modestly sized clinical trial indicates that PCSK9-inhibitors can help lower cholesterol, even for those who experienced side effects with older drugs.
Wearable devices can help individuals adopt healthy habits, preliminary research has found. In the future, they will become even more important tools.
U-M cardiologists say anticoagulation clinics still hold a vital role in patient care, even as new drugs claim to reduce the need.